Tags : Greater China

Pfizer And LianBio Collaborate to Expand the Development of Novel

Shots: Pfizer & LianBio collaborate to focus at developing & commercializing transformative therapies in Greater China. Both the companies will leverage their clinical development, regulatory and commercial expertise Pfizer will contribute ~$70M of non-dilutive capital toward in-licensing & co-development. At LianBio’s discretion, products will be presented to Pfizer for joint development Pfizer will have a […]Read More

ImmunoGen Signs an Agreement with Huadong to Develop & Commercialize

Shots: ImmunoGen to receive $40M up front, ~$265M as development, regulatory & commercial milestones and is eligible to receive royalties on sales of mirvetuximab in Greater China and will retain all rights to mirvetuximab in the US & ROW The collaboration accelerates the development path for mirvetuximab in Greater China and expands Huadong’s oncology portfolio […]Read More

Zai Lab Signs an Exclusive License Agreement with Turning Point

Shots: Turning Point to receive $25M as upfront, $151M as development, regulatory and commercial milestones along with royalties on sales of repotrectinib in Greater China. Zai Lab to get exclusive rights to develop and commercialize repotrectinib in Greater China including China, Hong Kong, Macau, and Taiwan Zai Lab anticipates opening additional sites for the TRIDENT-1 […]Read More

Samsung Biologics Collaborates with APRINOIA Therapeutics to Expand its Presence

Shots: Samsung Biologics entered into an agreement with APRINOIA Therapeutics to develop an anti-tau mAb for treating primary and secondary tauopathies, including PSP and AD APRINOIA will utilize its Ab platform for selecting the candidate and targets specific pathological tau aggregates with novel conformation-dependent epitopes with an aim to slow down disease progression The collaboration […]Read More

CMS Signs a License Agreement with Zydus for Desidustat in

Shots: Zydus to receive up front, development & commercial milestones and royalties on sales of Desidustat while CMS to get a license to develop & commercialize the therapy for CKD patients in Greater China The collaboration provides Zydus access to Greater China and facilitates the availability of Desidustat to the millions of CKD patients living […]Read More

I-Mab Signs an Exclusive License Agreement with MacroGenics to Develop

Shots: MacroGenics to receive $15M up front, up to $135M as development & regulatory milestones and royalties on sales in Greater China. I-Mab to get development & commercialization rights for Enoblituzumab in China, Hong Kong, Macau and Taiwan As per the agreement, I-Mab will lead global clinical studies including its territories. In H2’19, MacroGenics plans […]Read More